肝脾双介入对原发性肝癌血清sIL-2R和VEGF水平的影响

Effect of Liver and Spleen Interventional Therapy on the Levels of Serum sIL-2R and VEGF in Hepatocellular Carcinoma

【目的】研究原发性肝细胞癌（HCC）患者行肝动脉灌注化疗（TAcE）联合脾动脉化疗药物灌注治疗前后血清可溶性白细胞介素2受体（slL-2R）和血管内皮细胞生长因子（VEGF）水平变化及其临床意义。【方法】30例HCC患者行单纯肝动脉化疗栓塞（TACE），45例行TACE联合脾动脉化疗药物灌注治疗，分别于治疗前后测定slL-2R和VEGF，并与30名健康体检者比较。【结果】HCC患者sIL-2R及VEGF水平明显高于对照组（P〈0．01）；治疗后sIL-2R和VEGFR水平均较治疗前明显下降（P〈0．01）；肝脾双介入治疗后sIL-2R和VEGFR水平下降更显著（P〈0．05）。【结论】HCC患者TACE联合脾动脉化疗药物灌注治疗疗效明显，优于单纯TACE治疗。

[Objective] To investigate the changes of serum sIL-2R and VEGF in patients with hepatocel- lular carcinoma（HCC） before and after TACE combined with splenic arterial infusion chemotherapy. [Methods]Thirty patients with HCC received TACE treatment, and 45 patients with HCC received TACE combined with splenic arterial infusion chemotherapy. The levels of slL-2R and VEGF were determined before and after treatment in HCC patients, and compared with 30 normal controls. [Results] The levels of sIL-2R and VEGF in HCC patients were significantly higher than those in normal control group（ P 〈0.01）. The levels of sIL-2R and VEGF in HCC patients after treatment were significantly lower than those before treatment（ P 〈0.01）. The levels of sIL-2R and VEGF dropped more remarkably after liver and spleen interventional therapy（ P〈0.05）. [Conclusion] TACE combined with splenic arterial infusion chemotherapy for HCC patients has obvious effect, and is better than TACE.